Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04072445 · ClinicalTrials.gov registry record · Phase 2
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT04072445: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT04072445 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04072445, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase II trial studies how well trifluridine/tipiracil and irinotecan work in treating patients with biliary tract cancer that has spread to other places in the body (advanced) and has not responded to treatment (refractory). Trifluridine/tipiracil and irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Irinotecan
- DRUG Irinotecan Hydrochloride
- DRUG Trifluridine and Tipiracil Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-10-18 |
| Est. Completion | 2021-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04072445
The ClinicalTrials.gov registry entry for NCT04072445 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Irinotecan is the first listed.
NCT04072445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04072445 about?
NCT04072445 is a clinical study titled "Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer". This phase II trial studies how well trifluridine/tipiracil and irinotecan work in treating patients with biliary tract cancer that has spread to other places in the body (advanced) and has not responded to treatment (refractory). Trifluridine/tipiracil and irinotecan may stop the growth of tumor ce...
What is the current status of trial NCT04072445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-10-18. Estimated completion is 2021-08-13.
What interventions are being tested in trial NCT04072445?
The interventions under investigation include: Irinotecan (DRUG), Irinotecan Hydrochloride (DRUG), Trifluridine and Tipiracil Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04072445?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.